These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 16303884)

  • 1. Warfarin initiation and the potential role of genomic-guided dosing.
    Lee CR
    Clin Med Res; 2005 Nov; 3(4):205-6. PubMed ID: 16303884
    [No Abstract]   [Full Text] [Related]  

  • 2. The pharmocogenomics of warfarin: closing in on personalized medicine.
    Rettie AE; Tai G
    Mol Interv; 2006 Aug; 6(4):223-7. PubMed ID: 16960144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A case report of a patient carrying CYP2C9*3/4 genotype with extremely low warfarin dose requirement.
    Lee SY; Nam MH; Kim JS; Kim JW
    J Korean Med Sci; 2007 Jun; 22(3):557-9. PubMed ID: 17596671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients.
    Miao L; Yang J; Huang C; Shen Z
    Eur J Clin Pharmacol; 2007 Dec; 63(12):1135-41. PubMed ID: 17899045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cost-effectiveness of warfarin pharmacogenomics.
    Veenstra DL
    J Thromb Haemost; 2007 Sep; 5(9):1974-5. PubMed ID: 17650084
    [No Abstract]   [Full Text] [Related]  

  • 6. Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin.
    Gage BF; Eby C; Milligan PE; Banet GA; Duncan JR; McLeod HL
    Thromb Haemost; 2004 Jan; 91(1):87-94. PubMed ID: 14691573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Warfarin-dosing algorithm based on a population pharmacokinetic/pharmacodynamic model combined with Bayesian forecasting.
    Sasaki T; Tabuchi H; Higuchi S; Ieiri I
    Pharmacogenomics; 2009 Aug; 10(8):1257-66. PubMed ID: 19663670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic testing for warfarin dosing? Not yet ready for prime time.
    Bussey HI; Wittkowsky AK; Hylek EM; Walker MB
    Pharmacotherapy; 2008 Feb; 28(2):141-3. PubMed ID: 18225960
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmacogenomics of warfarin: uncovering a piece of the warfarin mystery.
    Gulseth MP; Grice GR; Dager WE
    Am J Health Syst Pharm; 2009 Jan; 66(2):123-33. PubMed ID: 19139476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Q: Should we use pharmacogenetic testing when prescribing warfarin?
    Rouse M; Cristiani C; Teng KA
    Cleve Clin J Med; 2013 Aug; 80(8):483-6. PubMed ID: 23908104
    [No Abstract]   [Full Text] [Related]  

  • 11. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation.
    Anderson JL; Horne BD; Stevens SM; Grove AS; Barton S; Nicholas ZP; Kahn SF; May HT; Samuelson KM; Muhlestein JB; Carlquist JF;
    Circulation; 2007 Nov; 116(22):2563-70. PubMed ID: 17989110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenetics of coumarinic oral anticoagulants.
    Manolopoulos VG; Ragia G; Tavridou A
    Pharmacogenomics; 2010 Apr; 11(4):493-6. PubMed ID: 20350128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenomic testing for warfarin dosing: we are ready now.
    Wu AH
    Expert Rev Cardiovasc Ther; 2009 Dec; 7(12):1483-5. PubMed ID: 19954308
    [No Abstract]   [Full Text] [Related]  

  • 14. Impact of age, CYP2C9 genotype and concomitant medication on the rate of rise for prothrombin time during the first 30 days of warfarin therapy.
    Wilke RA; Berg RL; Vidaillet HJ; Caldwell MD; Burmester JK; Hillman MA
    Clin Med Res; 2005 Nov; 3(4):207-13. PubMed ID: 16303885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype.
    Voora D; Eby C; Linder MW; Milligan PE; Bukaveckas BL; McLeod HL; Maloney W; Clohisy J; Burnett RS; Grosso L; Gatchel SK; Gage BF
    Thromb Haemost; 2005 Apr; 93(4):700-5. PubMed ID: 15841315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of oral vitamin K on S- and R-warfarin pharmacokinetics and pharmacodynamics: enhanced safety of warfarin as a CYP2C9 probe.
    Kim JS; Nafziger AN; Gaedigk A; Dickmann LJ; Rettie AE; Bertino JS
    J Clin Pharmacol; 2001 Jul; 41(7):715-22. PubMed ID: 11452703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Oral anticoagulation and pharmacogenetics: importance in the clinical setting].
    Benusiglio PR; Desmeules J; de Moerloose P; Dayer P
    Rev Med Suisse; 2007 Sep; 3(124):2030, 2033-4, 2036. PubMed ID: 17955831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polymorphisms in VKORC1 have more impact than CYP2C9 polymorphisms on early warfarin International Normalized Ratio control and bleeding rates.
    Lund K; Gaffney D; Spooner R; Etherington AM; Tansey P; Tait RC
    Br J Haematol; 2012 Jul; 158(2):256-261. PubMed ID: 22571356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimization of warfarin dose by population-specific pharmacogenomic algorithm.
    Pavani A; Naushad SM; Rupasree Y; Kumar TR; Malempati AR; Pinjala RK; Mishra RC; Kutala VK
    Pharmacogenomics J; 2012 Aug; 12(4):306-11. PubMed ID: 21358752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genotype-guided dosing of warfarin.
    Mega JL; Giugliano RP
    Clin Chem; 2014 Jul; 60(7):920-2. PubMed ID: 24691686
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.